Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma
Standard
Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. / Li, Wenchao; Blessin, Niclas C; Simon, Ronald; Kluth, Martina; Fischer, Kristine; Hube-Magg, Claudia; Makrypidi-Fraune, Georgia; Wellge, Björn; Mandelkow, Tim; Debatin, Nicolaus F; Pott, Laura; Höflmayer, Doris; Lennartz, Maximilian; Sauter, Guido; Izbicki, Jakob R; Minner, Sarah; Büscheck, Franziska; Uhlig, Ria; Dum, David; Krech, Till; Luebke, Andreas M; Wittmer, Corinna; Jacobsen, Frank; Burandt, Eike; Steurer, Stefan; Wilczak, Waldemar; Hinsch, Andrea.
in: BMC CANCER, Jahrgang 18, Nr. 1, 04.12.2018, S. 1209.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma
AU - Li, Wenchao
AU - Blessin, Niclas C
AU - Simon, Ronald
AU - Kluth, Martina
AU - Fischer, Kristine
AU - Hube-Magg, Claudia
AU - Makrypidi-Fraune, Georgia
AU - Wellge, Björn
AU - Mandelkow, Tim
AU - Debatin, Nicolaus F
AU - Pott, Laura
AU - Höflmayer, Doris
AU - Lennartz, Maximilian
AU - Sauter, Guido
AU - Izbicki, Jakob R
AU - Minner, Sarah
AU - Büscheck, Franziska
AU - Uhlig, Ria
AU - Dum, David
AU - Krech, Till
AU - Luebke, Andreas M
AU - Wittmer, Corinna
AU - Jacobsen, Frank
AU - Burandt, Eike
AU - Steurer, Stefan
AU - Wilczak, Waldemar
AU - Hinsch, Andrea
PY - 2018/12/4
Y1 - 2018/12/4
N2 - Hodgkin's lymphoma (HL) is characterized by a high background of inflammatory cells which play an important role for the pathogenesis of the disease. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor and a putative target for novel immunotherapies. To study patterns of TIGIT expression in the T cell background surrounding malignant cells including Hodgkin cells, Reed-Sternberg cells and histiocytic cells, a microenvironment (ME) tissue microarray (TMA) was constructed from tissue punches measuring 2 mm in diameter obtained from formalin-fixed tissue samples of Hodgkin's lymphoma lymph nodes (n = 40) and normal human tonsil (n = 2). The ME-TMA was stained by brightfield and fluorescence multiplex immunohistochemistry (IHC) to evaluate expression levels of TIGIT and PD-1 as well as standard lymphocyte markers (CD3, CD8, CD4, FOXP3) in the lymphocytic background. All analyzed cases of HL contained 9-99% (median: 86%) of TIGIT+ lymphoid cells. In general, TIGIT localized to the same cells as PD-1. Strikingly, expression levels of TIGIT and PD-1 were highly variable among the analyzed samples. Highest levels of TIGIT and PD-1 were found in one sample of nodular lymphocytic-predominant HL (NLPHL). In conclusion, TIGIT expression is highly variable between patients with Hodgkin's lymphoma. Our results encourage further studies evaluating the role of TIGIT as a target for immunotherapies in Hodgkin's lymphoma.
AB - Hodgkin's lymphoma (HL) is characterized by a high background of inflammatory cells which play an important role for the pathogenesis of the disease. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor and a putative target for novel immunotherapies. To study patterns of TIGIT expression in the T cell background surrounding malignant cells including Hodgkin cells, Reed-Sternberg cells and histiocytic cells, a microenvironment (ME) tissue microarray (TMA) was constructed from tissue punches measuring 2 mm in diameter obtained from formalin-fixed tissue samples of Hodgkin's lymphoma lymph nodes (n = 40) and normal human tonsil (n = 2). The ME-TMA was stained by brightfield and fluorescence multiplex immunohistochemistry (IHC) to evaluate expression levels of TIGIT and PD-1 as well as standard lymphocyte markers (CD3, CD8, CD4, FOXP3) in the lymphocytic background. All analyzed cases of HL contained 9-99% (median: 86%) of TIGIT+ lymphoid cells. In general, TIGIT localized to the same cells as PD-1. Strikingly, expression levels of TIGIT and PD-1 were highly variable among the analyzed samples. Highest levels of TIGIT and PD-1 were found in one sample of nodular lymphocytic-predominant HL (NLPHL). In conclusion, TIGIT expression is highly variable between patients with Hodgkin's lymphoma. Our results encourage further studies evaluating the role of TIGIT as a target for immunotherapies in Hodgkin's lymphoma.
KW - Journal Article
U2 - 10.1186/s12885-018-5111-1
DO - 10.1186/s12885-018-5111-1
M3 - SCORING: Journal article
C2 - 30514251
VL - 18
SP - 1209
JO - BMC CANCER
JF - BMC CANCER
SN - 1471-2407
IS - 1
ER -